6 completed, 2 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Terminated 2 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow TAK-117: new trials by email Literature Review of TAK-117 trials Research Report on TAK-117
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors paclitaxel, TAK-228, TAK-117 - Advanced Solid Tumor | Phase 1 | Completed | Avera McKennan Hospital & University Health Center | 19 | 2017-07-06 | 2024-07-26 |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Everolimus, MLN0128, MLN1117 - Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 96 | 2016-06-30 | 2021-11-19 |
| A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer Paclitaxel, Sapanisertib, MLN1117 - Endometrial Neoplasms | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 241 | 2016-04-01 | 2021-11-24 |
| A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants TAK-117, Lansoprazole - Neoplasm, Advanced or Metastatic | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 54 | 2016-01-08 | 2018-01-08 |
| MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma MLN1117, TAK-659, Alisertib - Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 32 | 2015-10-15 | 2019-09-20 |
| Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer Docetaxel, TAK-117 - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Millennium Pharmaceuticals, Inc. | 14 | 2015-06-03 | 2018-02-07 |
| A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies TAK-228, TAK-117 - Advanced Nonhematologic Malignancies | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 101 | 2013-06-28 | 2019-10-30 |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer TAK-117 - Metastatic Solid Tumors | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 125 | 2011-10-01 | 2017-03-09 |
Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Clear-cell metastatic renal cell carcinoma (1) · Endometrial Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Neoplasm Metastasis (1)
Millennium Pharmaceuticals, Inc. (7) · Avera McKennan Hospital & University Health Center (1)
United States (7) · Spain (5) · United Kingdom (4) · Canada (3) · Italy (2) · Netherlands (2) · Australia (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Norway (1) · Poland (1)
2014 (2), 2015 (2)